HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bogacka, I. Articles by Smith, S. R. Search for Related Content PubMed PubMed Citation Articles by Bogacka, I. Articles by Smith, S. R. Social Bookmarking                What's this?

Pioglitazone Induces Mitochondrial Biogenesis in Human Subcutaneous Adipose Tissue In Vivo

From the Molecular Endocrinology Laboratory, Pennington Biomedical Research Center, Baton Rouge, Louisiana

Thiazolidenediones such as pioglitazone improve insulin sensitivity in diabetic patients by several mechanisms, including increased uptake and metabolism of free fatty acids in adipose tissue. The purpose of the present study was to determine the effect of pioglitazone on mitochondrial biogenesis and expression of genes involved in fatty acid oxidation in subcutaneous fat. Patients with type 2 diabetes were randomly divided into two groups and treated with placebo or pioglitazone (45 mg/day) for 12 weeks. Mitochodrial DNA copy number and expression of genes involved in mitochondrial biogenesis were quantified by real-time PCR. Pioglitazone treatment significantly increased mitochondrial copy number and expression of factors involved in mitochondrial biogenesis, including peroxisome proliferator–activated receptor (PPAR)- coactivator-1 and mitochondrial transcription factor A. Treatment with pioglitazone stimulated the expression of genes in the fatty acid oxidation pathway, including carnitine palmitoyltransferase-1, malonyl-CoA decarboxylase, and medium-chain acyl-CoA dehydrogenase. The expression of PPAR-, a transcriptional regulator of genes encoding mitochondrial enzymes involved in fatty acid oxidation, was higher after pioglitazone treatment. Finally, the increased mitochondrial copy number and the higher expression of genes involved in fatty acid oxidation in human adipocytes may contribute to the hypolipidemic effects of pioglitazone.

Abbreviations: ADRB3, adrenergic ß-3 receptor; CPT-1, carnitine palmitoylotransferase I; FPG, fasting plasma glucose; MCAD, medium-chain acyl-CoA dehydrogenase; MLYCD, malonyl-CoA decarboxylase; mtDNA, mitochondrial DNA; mtTFA, mitochondrial transcription factor A; NRF, nuclear respiratory factor; PGC-1, peroxisome proliferator–activated receptor coactivator-1; PPAR, peroxisome proliferator–activated receptor; TZD, thiazolidinedione; UCP, uncoupling protein

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. L. Paddock, S. E. Wiley, H. L. Axelrod, A. E. Cohen, M. Roy, E. C. Abresch, D. Capraro, A. N. Murphy, R. Nechushtai, J. E. Dixon, et al. MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pioglitazone PNAS, September 4, 2007; 104(36): 14342 - 14347. [Abstract] [Full Text] [PDF]

				N. P.E. Kadoglou, F. Iliadis, C. D. Liapis, D. Perrea, N. Angelopoulou, and M. Alevizos Beneficial Effects of Combined Treatment With Rosiglitazone and Exercise on Cardiovascular Risk Factors in Patients With Type 2 Diabetes Diabetes Care, September 1, 2007; 30(9): 2242 - 2244. [Full Text] [PDF]

				J. X. Rong, Y. Qiu, M. K. Hansen, L. Zhu, V. Zhang, M. Xie, Y. Okamoto, M. D. Mattie, H. Higashiyama, S. Asano, et al. Adipose Mitochondrial Biogenesis Is Suppressed in db/db and High-Fat Diet-Fed Mice and Improved by Rosiglitazone Diabetes, July 1, 2007; 56(7): 1751 - 1760. [Abstract] [Full Text] [PDF]

				S. Ghosh, N. Patel, D. Rahn, J. McAllister, S. Sadeghi, G. Horwitz, D. Berry, K. X. Wang, and R. H. Swerdlow The Thiazolidinedione Pioglitazone Alters Mitochondrial Function in Human Neuron-Like Cells Mol. Pharmacol., June 1, 2007; 71(6): 1695 - 1702. [Abstract] [Full Text] [PDF]

				I. Bogacka, T. W. Gettys, L. de Jonge, T. Nguyen, J. M. Smith, H. Xie, F. Greenway, and S. R. Smith The Effect of {beta}-Adrenergic and Peroxisome Proliferator-Activated Receptor-{gamma} Stimulation on Target Genes Related to Lipid Metabolism in Human Subcutaneous Adipose Tissue Diabetes Care, May 1, 2007; 30(5): 1179 - 1186. [Abstract] [Full Text] [PDF]

				B. Ukropcova, O. Sereda, L. de Jonge, I. Bogacka, T. Nguyen, H. Xie, G. A. Bray, and S. R. Smith Family History of Diabetes Links Impaired Substrate Switching and Reduced Mitochondrial Content in Skeletal Muscle Diabetes, March 1, 2007; 56(3): 720 - 727. [Abstract] [Full Text] [PDF]

				J. D. Brown and J. Plutzky Peroxisome Proliferator Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets Circulation, January 30, 2007; 115(4): 518 - 533. [Abstract] [Full Text] [PDF]

				Z. H. Huang, C. A. Reardon, and T. Mazzone Endogenous ApoE Expression Modulates Adipocyte Triglyceride Content and Turnover Diabetes, December 1, 2006; 55(12): 3394 - 3402. [Abstract] [Full Text] [PDF]

				N. E. Wolins, B. K. Quaynor, J. R. Skinner, A. Tzekov, M. A. Croce, M. C. Gropler, V. Varma, A. Yao-Borengasser, N. Rasouli, P. A. Kern, et al. OXPAT/PAT-1 Is a PPAR-Induced Lipid Droplet Protein That Promotes Fatty Acid Utilization Diabetes, December 1, 2006; 55(12): 3418 - 3428. [Abstract] [Full Text] [PDF]

				M. Laplante, W. T. Festuccia, G. Soucy, Y. Gelinas, J. Lalonde, J. P. Berger, and Y. Deshaies Mechanisms of the Depot Specificity of Peroxisome Proliferator-Activated Receptor {gamma} Action on Adipose Tissue Metabolism. Diabetes, October 1, 2006; 55(10): 2771 - 2778. [Abstract] [Full Text] [PDF]

				T. Allen, F. Zhang, S. A. Moodie, L. E. Clemens, A. Smith, F. Gregoire, A. Bell, G. E.O. Muscat, and T. A. Gustafson Halofenate Is a Selective Peroxisome Proliferator-Activated Receptor {gamma} Modulator With Antidiabetic Activity Diabetes, September 1, 2006; 55(9): 2523 - 2533. [Abstract] [Full Text] [PDF]

				I. Dahlman, M. Forsgren, A. Sjogren, E. A. Nordstrom, M. Kaaman, E. Naslund, A. Attersand, and P. Arner Downregulation of Electron Transport Chain Genes in Visceral Adipose Tissue in Type 2 Diabetes Independent of Obesity and Possibly Involving Tumor Necrosis Factor-{alpha} Diabetes, June 1, 2006; 55(6): 1792 - 1799. [Abstract] [Full Text] [PDF]

				E. Hondares, O. Mora, P. Yubero, M. R. de la Concepcion, R. Iglesias, M. Giralt, and F. Villarroya Thiazolidinediones and Rexinoids Induce Peroxisome Proliferator-Activated Receptor-Coactivator (PGC)-1{alpha} Gene Transcription: An Autoregulatory Loop Controls PGC-1{alpha} Expression in Adipocytes via Peroxisome Proliferator-Activated Receptor-{gamma} Coactivation Endocrinology, June 1, 2006; 147(6): 2829 - 2838. [Abstract] [Full Text] [PDF]

				F. F. Samaha, P. O. Szapary, N. Iqbal, M. M. Williams, L. T. Bloedon, A. Kochar, M. L. Wolfe, and D. J. Rader Effects of Rosiglitazone on Lipids, Adipokines, and Inflammatory Markers in Nondiabetic Patients With Low High-Density Lipoprotein Cholesterol and Metabolic Syndrome Arterioscler. Thromb. Vasc. Biol., March 1, 2006; 26(3): 624 - 630. [Abstract] [Full Text] [PDF]

				I. Bogacka, B. Ukropcova, M. McNeil, J. M. Gimble, and S. R. Smith Structural and Functional Consequences of Mitochondrial Biogenesis in Human Adipocytes in Vitro J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6650 - 6656. [Abstract] [Full Text] [PDF]